EUVIMEDEUVIMED entdecken
Crossref

Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis

Yun Wang, Jiawei Wu, Yu Hong, Jiaying Zhu, Youcai Zhang, Jun Zhang, Chujie Ding, Yuan Che, Guangji Wang, Aiqin Jiang, Haiping Hao iD, Lijuan Cao

British Journal of Pharmacology · 2024-06 · 181 (12) · 1768-1792

DOI: 10.1111/bph.16320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 14.02.2024. Verfasst von Yun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Ginsenosides, Gastrointestinal Microbiome, Homeostasis, Atherosclerosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: The National Key Research and Development Programme of China, The National Natural Science Foundation of China, Overseas Expertise Introduction Project for Discipline Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Panax ginseng is widely applied in the adjuvant treatment of cardiometabolic diseases in clinical practice without clear mechanisms. This study aims to clearly define the efficacy and underlying mechanism of P. ginseng and its active components in protecting against atherosclerosis. Experimental Approach The anti‐atherogenic efficacy of total ginseng saponin extract (TGS) and its components was evaluated on Ldlr −/− mice. Gut microbial structure was analysed by 16S rRNA sequencing and PCR. Bile acid profiles were revealed using targeted metabolomics with LC–MS/MS analysis. The contribution of gut microbiota to atherosclerosis was assessed by co‐housing experiments. Key Results Ginsenoside Rb1, representing protopanaxadiol (PPD)‐type saponins, increased intestinal Lactobacillus abundance, resulting in enhanced bile salt hydrolase (BSH) activity to promote intestinal conjugated bile acid hydrolysis and excretion, followed by suppression of enterohepatic farnesoid X receptor (FXR)–fibroblast growth factor 15 (FGF15) signal, and thereby increased cholesterol 7α‐hydroxylase (CYP7A1) transcriptional expression and facilitated metabolic elimination of cholesterol. Synergistically, protopanaxatriol (PPT)‐type saponins, represented by ginsenoside Rg1, protected against atherogenesis‐triggered gut leak and metabolic endotoxaemia. Ginsenoside Rg1 directly induced mucin production to nutritionally maintain Akkermansia muciniphila , which reciprocally inhibited gut permeation. Rb1/Rg1 combination, rather than a single compound, can largely mimic the holistic efficacy of TGS in protecting Ldlr −/− mice from atherogenesis. Conclusion and Implications Our study provides strong evidence supporting TGS and ginsenoside Rb1/Rg1 combinations as effective therapies against atherogenesis, via targeting different signal nodes by different components and may provide some elucidation of the holistic mode of herbal medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GinsenosidesGastrointestinal MicrobiomeHomeostasisAtherosclerosisMice, KnockoutPanaxAnimalsMaleMiceMice, Inbred C57BLBile Acids and SaltsReceptors, LDLFibroblast Growth FactorsAmidohydrolasesCholesterol 7-alpha-Hydroxylase

Stichwörter der Autor:innen

Akkermansia muciniphilaLactobacillusatherosclerosisbile acidsginsenosidegut microbiota

Substanzen

GinsenosidesBile Acids and SaltsReceptors, LDLFibroblast Growth Factorsfibroblast growth factor 15, mouseAmidohydrolasesCholesterol 7-alpha-Hydroxylase

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
  • School of Pharmacy, Nanjing Medical University, Nanjing, China.
  • State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, Research Unit of PK-PD Based Bioactive Components and Pharmacodynamic Target Discovery of Natural Medicine of Chinese Ac…
  • Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.

ORCID-Profile: Haiping Hao

Förderung

  • The National Key Research and Development Programme of China
  • The National Natural Science Foundation of China
  • Overseas Expertise Introduction Project for Discipline Innovation
  • The Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University
  • CAMS Innovation Fund for Medical Sciences
  • China Postdoctoral Science Foundation
  • National Key Research and Development Program of China
  • National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Wu, J., Hong, Y., Zhu, J., Zhang, Y., Zhang, J., Ding, C., Che, Y., Wang, G., Jiang, A., Hao, H., & Cao, L. (2024). Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis. British Journal of Pharmacology, 181(12), 1768-1792. https://doi.org/10.1111/bph.16320

Vancouver

Wang Y, Wu J, Hong Y, Zhu J, Zhang Y, Zhang J, et al. Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis. British Journal of Pharmacology. 2024;181(12):1768-1792. doi:10.1111/bph.16320

BibTeX
@article{Wang2024,
  author = {Wang, Yun and Wu, Jiawei and Hong, Yu and Zhu, Jiaying and Zhang, Youcai and Zhang, Jun and Ding, Chujie and Che, Yuan and Wang, Guangji and Jiang, Aiqin and Hao, Haiping and Cao, Lijuan},
  title = {Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {12},
  pages = {1768--1792},
  doi = {10.1111/bph.16320}
}
Kostenlos starten →